
## Ernesto Trallero-AraguÃ;s

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8791773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center. Seminars in Arthritis and Rheumatism, 2022, 53, 151940.	1.6	5
2	Inflammatory myopathy, mixed connective tissue disease, and antisynthetase syndrome. Handbook of Systemic Autoimmune Diseases, 2022, , 105-151.	0.1	0
3	OUP accepted manuscript. Rheumatology, 2022, , .	0.9	2
4	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	0.8	8
5	Myo-Spain: Registro de pacientes con miopatÃa inflamatoria idiopática de España. MetodologÃa. ReumatologÃa ClÃnica, 2021, , .	0.2	0
6	Myositis and myasteniform syndrome related to pembrolizumab. BMJ Case Reports, 2021, 14, e241766.	0.2	5
7	Myo-Spain: Spanish Registry of patients with idiopathic inflammatory myopathy. Methodology. ReumatologAa ClAnica (English Edition), 2021, , .	0.2	0
8	Differential diagnosis of necrotizing myopathy. Current Opinion in Rheumatology, 2021, 33, 544-553.	2.0	11
9	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	1.6	4
10	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmunity Reviews, 2020, 19, 102455.	2.5	51
11	Anti-TIF-1Î <sup>3</sup> Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice. Frontiers in Immunology, 2020, 11, 625896.	2.2	2
12	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina ClÃnica, 2020, 155, 541-547.	0.3	8
13	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Seminars in Arthritis and Rheumatism, 2020, 50, 564-570.	1.6	129
14	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	1.6	12
15	Cancer-Associated Myositis. , 2020, , 237-245.		2
16	Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. Clinical and Experimental Rheumatology, 2020, 38, 67-73.	0.4	6
17	Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. Neuromuscular Disorders, 2019, 29, 819-825.	0.3	12
18	PET Scan: Nuclear Medicine Imaging in Myositis. Current Rheumatology Reports, 2019, 21, 64.	2.1	10

#	Article	IF	CITATIONS
19	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
20	Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Review of Clinical Immunology, 2018, 14, 215-224.	1.3	112
21	Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology, 2018, 57, 388-396.	0.9	81
22	Opportunistic infections in patients with idiopathic inflammatory myopathies. International Journal of Rheumatic Diseases, 2018, 21, 487-496.	0.9	31
23	The diagnostic work-up of cancer-associated myositis. Current Opinion in Rheumatology, 2018, 30, 630-636.	2.0	37
24	Classification and management of adult inflammatory myopathies. Lancet Neurology, The, 2018, 17, 816-828.	4.9	267
25	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.4	30
26	SÃndrome por anticuerpos antisintetasa. Multidisciplinariedad y compromiso. Medicina ClÃnica, 2017, 148, 164-165.	0.3	0
27	Antisynthetase syndrome. Multidisciplinary evaluation and comittment. Medicina ClÃnica (English) Tj ETQq1 1 C	.784314 r 0.1	gBT /Overloc
28	Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Seminars in Arthritis and Rheumatism, 2016, 46, 225-231.	1.6	91
29	Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools. Expert Review of Clinical Immunology, 2015, 11, 737-747.	1.3	14
30	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	145
31	Identification of a novel myositis-associated antibody directed against cortactin. Autoimmunity Reviews, 2014, 13, 1008-1012.	2.5	30
32	Anti-TIF1Î <sup>3</sup> antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Annals of the Rheumatic Diseases, 2012, 71, 993-996.	0.5	48
33	The Stone Man (Myositis ossificans progressiva). Joint Bone Spine, 2012, 79, 415.	0.8	1
34	Usefulness of antiâ€p155 autoantibody for diagnosing cancerâ€associated dermatomyositis: A systematic review and metaâ€analysis. Arthritis and Rheumatism, 2012, 64, 523-532.	6.7	286
35	Cancer-Associated Myositis and Anti-p155 Autoantibody in a Series of 85 Patients With Idiopathic Inflammatory Myopathy. Medicine (United States), 2010, 89, 47-52.	0.4	75
36	Malignancy and myositis: novel autoantibodies and new insights. Current Opinion in Rheumatology, 2010, 22, 627-632.	2.0	89

#	Article	IF	CITATIONS
37	Nailfold Capillary Microscopy in Adults with Inflammatory Myopathy. Seminars in Arthritis and Rheumatism, 2010, 39, 398-404.	1.6	58
38	Conventional Cancer Screening versus PET/CT in Dermatomyositis/Polymyositis. American Journal of Medicine, 2010, 123, 558-562.	0.6	133
39	Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy. Rheumatology, 2009, 48, 676-679.	0.9	18
40	Obstructive sleep apnea in patients with inflammatory myopathies. Muscle and Nerve, 2009, 39, 144-149.	1.0	17
41	Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris. Atherosclerosis, 2009, 207, 514-518.	0.4	21

Clinical Significance of Thyroid Disease in Patients With Inflammatory Myopathy. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5